S 95041
Alternative Names: S-95041Latest Information Update: 05 Dec 2025
At a glance
- Originator Servier
- Class Monoclonal antibodies
- Mechanism of Action CD40 antigen inhibitors; Interleukin 7 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Chronic urticaria
Most Recent Events
- 01 Sep 2025 Discontinued - Preclinical for Autoimmune disorders in France (Parenteral) (Servier pipeline, September 2025)
- 13 Jul 2023 Discontinued - Preclinical for Chronic-urticaria in France (Parenteral) (Servier pipeline, July 2023)
- 13 Jul 2023 Preclinical trials in Autoimmune disorders in France (Parenteral) (Servier pipeline, July 2023)